Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (40.1), the stock would be worth NZ$38.31 (6% upside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 37.6 | NZ$35.98 |
0%
|
| 3-Year Average | 40.1 | NZ$38.31 |
+6%
|
| 5-Year Average | 39 | NZ$37.27 |
+4%
|
| Industry Average | 9.8 | NZ$9.33 |
-74%
|
| Country Average | 13.9 | NZ$13.25 |
-63%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| NZ |
|
Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH
|
21.1B NZD | 37.6 | 48.4 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 56.5 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 16.5 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 24.8 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 14.7 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 20.3 | 25.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 13.2 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 30.6 | 44.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 38.2 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 12.8 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 16.7 | 21.6 |
Market Distribution
| Min | 1.5 |
| 30th Percentile | 8.1 |
| Median | 13.9 |
| 70th Percentile | 20.7 |
| Max | 325.4 |
Other Multiples
Fisher & Paykel Healthcare Corporation Ltd
Glance View
Nestled in the heart of New Zealand, Fisher & Paykel Healthcare Corporation Ltd. has emerged as a formidable player in the global healthcare market, largely due to its innovative spirit and relentless focus on respiratory care solutions. Originally part of Fisher & Paykel Industries, the healthcare division carved its own path in 2001, quickly becoming synonymous with high-quality medical devices. The company’s journey can be compared to a constant rhythm of innovation, particularly in areas that address obstructive sleep apnea, acute respiratory distress, and surgical humidification. Its revenue streams are primarily bolstered by a diverse array of products, including sleep apnea masks, humidifier systems for intensive care units, and related respiratory accessories. These offerings are not just technological marvels but are designed to improve patient outcomes and their quality of life, which resonates well with healthcare providers worldwide. Over the years, Fisher & Paykel Healthcare has strategically expanded its operations beyond its Kiwi roots, anchoring its presence in over 120 countries. This global footprint, coupled with a robust pipeline of patented products, enables sustained revenue growth and stability. The company’s financial health is driven by a business model that emphasizes research and development, ensuring that it remains at the forefront of medical innovation. By fostering close relationships with healthcare professionals and institutions, Fisher & Paykel not only gains invaluable insights to refine its products but also cultivates a loyal customer base. This enduring approach cements its position not only as a leader in the healthcare sector but also as a trusted partner in the critical mission to enhance patient care worldwide.